FDC has entered into definitive documents (including a trademark assignment deed) on October 16, 2019 with GlaxoSmithKline Pharmaceuticals (GSK) for acquiring the registered Trademark ‘ENTEROPLUS’ from GSK. The Company would have acquired all the rights of this Trademark/Brand 'ENTEROPLUS'.
FDC is engaged in manufacture of specialized formulations, and oral rehydration salts (ORS).